Skip to content
zameds

Drospirenone, ethinylestradiol (Drasira, Ginorelle)

Drospirenone, ethinylestradiol

Cipla Medpro (Pty) Ltd

Registration

Applicant
Cipla Medpro (Pty) Ltd
Registrations
2

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Drasira

Each tablet contains DROSPIRENONE 3,0 mg and ETHINYLESTRADIOL 0,02 mg

Not listed47014147/21.8.2/0141RegisteredNot determinedNone
Ginorelle

Each active tablet contains DROSPIRENONE 3,0 mg and ETHINYLESTRADIOL 0,03 mg

Not listed50034350/18.8/0343RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles